Therapy with the indicated medicinal product should be started as soon as possible after a diagnosis of COVID-19 in the patient, i.e. When the symptoms of the disease occurred no earlier than in the last 5 days.

The criteria for including patients in therapy are as follows:

  • diagnosis of COVID-19
  • the occurrence of COVID-19 symptoms not earlier than in the last 5 days
  • an adult patient and belonging to the risk group of severe COVID-19, i.e.
  • age> 65 years
  • active neoplastic process (malignant tumors)
  • immunosuppressive treatment
  • heart failure
  • ischemic heart disease
  • cardiomyopathies
  • diabetes
  • COPD
  • obesity (BMI ≥35)
  • chronic kidney disease
  • congenital immunity errors
  • residents of social welfare homes

Patients who are medically indicated for COVID-19 hospitalization are not eligible for Lagevrio, Molnupiravir therapy.

There are no data on the use of the medicine in pregnant women.

The recommended dose of Molnupiravir is 800 mg (four 200 mg capsules) taken orally every 1 hour for 5 days.
The treatment cannot be extended for a period longer than 5 days.
Treatment with Molnupiravir should be started as soon as possible after a diagnosis of COVID-19, but no later than 5 days after the onset of symptoms.

To reduce the possibility of the emergence of resistance, patients should be instructed to complete the entire treatment cycle even if their symptoms improve and/or feel better.

The most common adverse reactions reported during treatment and in the 14 days following the last dose
of Molnupiravir were diarrhea (3%), nausea (2%), dizziness (1%), and headache (1%), all of which were mild or moderate.

Based on the available data, no interactions of Molnupiravir with other medicinal products have been identified.

  • Molnupiravir is not a substrate of major medicine-metabolizing enzymes or medicine transporters.
  • Molnupiravir is not an inhibitor or an inducer of major medicine-metabolizing enzymes or medicine transporters.
  • The possible interaction of Molnupiravir with concomitant medications is considered unlikely.
  • On the covid19-druginteractions.org/checker, you can check potential drug interactions Molnupiraviru with other medicine.

General rules

  • Primary Health Care or other entities overseeing the treatment of patients from severe disease groups (hematological and oncological patients, after transplantation) report the need from the Governmental Reserves Agency (SARS) through the Vaccine Distribution System (SDS).
  • RARS delivers the drug to the Primary Healthcare Clinic or other medical entity
    – a small package, e.g. 6 treatments.
  • The drug is dispensed to the patient according to the inclusion criteria and according to the schedule.

Recommendations for patient at-risk groups:

Do the test as soon as you develop symptoms of a respiratory infection, fever,
or other sudden deterioration of your health.
Contact the Clinic or other Medical Entity and if you get a positive result then make a teleconsultation
–   inform the Doctor about the symptoms.
The Doctor will decide on the basis of your symptoms whether you qualify for the drug.

 Assessment of indications for use with Molnupiravir:

  • symptoms of infection appeared not less than 5 days ago
  • the patient belongs to the risk group
  • a patient over 18 years of age

Assessment of the patient’s condition – if during teleconsultation the data from the interview
are ambiguous, a personal visit to the Home Medical Care should be arranged.

If the Doctor determines that the patient is eligible for the medicine, medicine is dispensed to the patient.
The therapy is monitored through telephone consultation or, if the patient’s condition requires it, a personal visit is provided.